Literature DB >> 17040286

Molecular tumor markers for asbestos-related mesothelioma: serum diagnostic markers.

Masahiro Maeda1, Okio Hino.   

Abstract

Mesothelioma is an aggressive tumor arising from the mesothelium, and is usually associated with previous exposure to asbestos. The incubation period of the tumor may be described as 30-40 years, and the prognosis is dismal. In addition to immunohistochemical markers, recently, serum markers for the diagnosis of mesothelioma have been reported as candidates. In contrast, the expression in renal carcinoma (ERC) gene has been discovered in the Eker rat model (Tsc2 gene mutant), which is a homolog of the human mesothelin/megakaryocyte potentiating factor gene, and a novel ELISA system (N-ERC/mesothelin) has been developed. It has also been found that N-ERC/mesothelin is very stable and plentiful in the blood. In the present paper the potential utility of molecular diagnostic markers is reviewed, including ELISA systems for asbestos-related mesothelioma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17040286     DOI: 10.1111/j.1440-1827.2006.02024.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  9 in total

1.  Diagnostic tumor marker of asbestos-related mesothelioma.

Authors:  Okio Hino; Masahiro Maeda
Journal:  Environ Health Prev Med       Date:  2008-02-28       Impact factor: 3.674

2.  The N-ERC index is a novel monitoring and prognostic marker for advanced malignant pleural mesothelioma.

Authors:  Takanori Mori; Ken Tajima; Michihiro Hirama; Tadashi Sato; Kenji Kido; Shin-Ichiro Iwakami; Shinichi Sasaki; Akihiko Iwase; Kazu Shiomi; Masahiro Maeda; Okio Hino; Kazuhisa Takahashi
Journal:  J Thorac Dis       Date:  2013-04       Impact factor: 2.895

3.  Mesothelioma - Update on Diagnostic Strategies.

Authors:  Carmen M Rosario; Xiaoqi Lin; David W Kamp
Journal:  Clin Pulm Med       Date:  2012-11

Review 4.  Prognostic value of several biomarkers for the patients with malignant pleural mesothelioma.

Authors:  Hui Liu; Licun Wu; Kai Ji; Wei Wang
Journal:  Tumour Biol       Date:  2015-09-11

5.  Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure.

Authors:  Melike Demir; Halide Kaya; Mahsuk Taylan; Aysun Ekinci; Sureyya Yılmaz; Fatma Teke; Cengizhan Sezgi; Abdullah Cetin Tanrikulu; Fatih Meteroglu; Abdurrahman Senyigit
Journal:  Lung       Date:  2016-03-31       Impact factor: 2.584

6.  Chemokine (C-C motif) ligand 3 detection in the serum of persons exposed to asbestos: A patient-based study.

Authors:  Jiegou Xu; David B Alexander; Masaaki Iigo; Hirokazu Hamano; Satoru Takahashi; Takako Yokoyama; Munehiro Kato; Ikuji Usami; Takeshi Tokuyama; Masahiro Tsutsumi; Mouka Tamura; Tetsuya Oguri; Akio Niimi; Yoshimitsu Hayashi; Yoshifumi Yokoyama; Ken Tonegawa; Katsumi Fukamachi; Mitsuru Futakuchi; Yuto Sakai; Masumi Suzui; Michihiro Kamijima; Naomi Hisanaga; Toyonori Omori; Dai Nakae; Akihiko Hirose; Jun Kanno; Hiroyuki Tsuda
Journal:  Cancer Sci       Date:  2015-06-05       Impact factor: 6.716

7.  Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis.

Authors:  Ai Cui; Xiao-Guang Jin; Kan Zhai; Zhao-Hui Tong; Huan-Zhong Shi
Journal:  BMJ Open       Date:  2014-02-24       Impact factor: 2.692

Review 8.  Environmental carcinogenesis - 100th anniversary of creating cancer.

Authors:  Misa Imai; Okio Hino
Journal:  Cancer Sci       Date:  2015-10-21       Impact factor: 6.716

Review 9.  CAR-T cell therapy in ovarian cancer: from the bench to the bedside.

Authors:  Xinxin Zhu; Han Cai; Ling Zhao; Li Ning; Jinghe Lang
Journal:  Oncotarget       Date:  2017-08-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.